Introduction
Cancer develops and persists as a result of accumulating genetic and epigenetic changes. 1 The reversibility of epigenetic changes has generated increasing interest in the development of agents that target epigenetic regulators such as histone deacetylases (HDACs). 2 HDACs are critical epigenetic erasers of lysine-acetyl marks of histones and non-histone substrates. 3 They can be classified on the basis of their homology to yeast counterparts. Class I HDACs (HDAC1, 22, 23, and 28) are highly homologous to Saccharomyces cerevisiae Rpd3. Class IIa HDACs (HDAC4, 25, 27, and 29) and class IIb HDACs (HDAC6 and 210) consist of S. cerevisiae Hda1 homologs. HDAC11 is the sole member of the class IV HDACs, based on homology to both class I and class II HDACs. 4 While class I, II, and IV HDACs are Zn 21 -dependent hydrolases, class III histone deacetylases, which consist of yeast Sir2 homologs (Sirtuins 1-7), form a structurally and mechanistically distinct class of nicotinamide adenine dinucleotide dependent hydrolases.
A classic function of HDACs relates to their role as transcriptional corepressors through deacetylation of lysine residues in histone tails. This results in a closed chromatin structure and diminished accessibility for the basal transcription machinery. Class I HDACs are present in repressor complexes such as SIN3A, NuRD, REST, and N-CoR/SMRT, which acquire their regional activities in part by interacting with sequence-specific transcription factors.
In agreement with a high sequence similarity between class I HDAC1 and HDAC2, genetic studies in mice revealed redundant functions of these enzymes in many cell types. [5] [6] [7] [8] [9] [10] In addition, many biological processes, such as DNA damage repair, autophagy, hematopoiesis, and cell cycle regulation, are collectively regulated by HDAC1 and HDAC2. 5, 6, 11, 12 Nevertheless, Hdac1-and Hdac2-specific functions have been identified. Deletion of Hdac1 results in embryonic lethality as early as E9.5 of development. 13 In effector T cells, Hdac1 regulates the inflammatory response in an in vivo allergic airway inflammation model, suggesting that Hdac1 has a specific function in controlling an inflammatory response by modulating cytokine expression.
14 In contrast to Hdac1 deficiency, Hdac2 loss of function results in viable mice with reduced body weight. [15] [16] [17] Others have reported that Hdac2 deficiency is not compatible with life due to cardiac myopathy. 7 In addition, Hdac2 plays a specific role in repression of genes involved in synaptogenesis, as evidenced by enhanced synapse formation, learning, and memory in Hdac2-deficient mice. 17 The use of pharmacological HDAC inhibition in cancer treatment is rationalized by observations showing high expression of individual There is an Inside Blood commentary on this article in this issue.
HDACs and recruitment of these proteins by oncogenic fusion proteins such as PML-RAR and AML-ETO in various cancer types. 18 In contrast, class I HDACs, such as HDAC1 and HDAC2, have been identified in complexes harboring tumor suppressors, such as the retinoblastoma protein (RB1), 19 p53, 20 BCL11B, 21 and RUNX1. 22 Hence, inhibition of HDACs may have tumor-promoting and tumor-suppressive consequences. The growing interest in the use of HDACi and other epigenetic drugs as therapeutic agents in the treatment of cancer, acquired drug resistance, HIV, diabetes, and neurological disorders such as Alzheimer disease [23] [24] [25] [26] necessitate full knowledge of HDACs in normal development to harness the therapeutic potential and future development of novel HDACi.
Methods Mice
The Hdac1 and Hdac2 cKO alleles as well as MxCre;Hdac1 L/L ;Hdac2 L/L mice have been described elsewhere. 5, 17 Thymocyte-specific deletion of Hdac1 and Hdac2 was obtained using LckCre transgenic mice 27 in combination with Hdac1 and/or Hdac2 cKO alleles. All cohorts were in a mixed FVB/n, C57BL/6, and 129/Sv background. All experiments were approved by a local ethical committee and performed according to national guidelines. , Em-Myc, or p53 2/2 mice. Single cell suspensions were cultured in Dulbecco's modified Eagle medium or Iscove modified Dulbecco medium medium containing 10% fetal bovine serum, glutamine, penicillin/streptomycin supplemented with 20% Methocult (M3434, Stem Cell Technologies). CD4 and CD8 flow cytometry analysis was used to confirm the T-cell identity of the cell lines. To determine HDACi sensitivity, tumor cell lines were treated with different concentrations of suberoylanilide hydroxamic acid (SAHA; Selleck) for 72 hours. Cell viability was measured using Cell Titer Blue assay (Promega). To infect lymphoma cell lines with lentiviral shRNA constructs, 5 3 10 5 cells were infected twice with 30 mL of concentrated lentiviral supernatants containing 4 mg/mL polybrene in a total volume of 530 mL for 24 hours and subsequently selected with 2.0 mg/mL puromycin for at least 48 hours. pLKO.1 Jdp2 and nontargeting (NT) shRNA vectors were obtained from the Netherlands Cancer Institute Robotics and Screening facility. Jdp2 mRNA levels were analyzed by quantitative polymerase chain reaction (qPCR) using the following primers: Jdp2_F 59-CGCTGACATCCGCAACATTG-39, Jdp2_R 59-CATCTGGCTG CAGCGACTTT-39.
In vivo BrdU labeling
Mice were injected intraperitoneally with 200 mL 5-bromo-2'-deoxyuridine (BrdU) solution (10 mg/mL). After 1.5 hours, thymocytes were intracellularly labeled with Bride antibodies (a-BrdU-APC) and with the DNA binding fluorescent dye 7-AAD (BrdU Flow Kit, BD Pharmingen). Subsequently, stained thymocytes were analyzed on a multicolor CyAn flow-cytometer (Beckman Coulter). Data were analyzed with FlowJo software (Treestar).
Histology
Tissues were fixed in ethanol-acetic acid-formol saline for 24 hours and subsequently embedded in paraffin. For immunohistochemistry, sections were preincubated with goat serum (Sanquin) for 30 minutes and subsequently incubated o/n with an Hdac1 antibody (Abcam), Hdac2 (Invitrogen), or p53 (VectorLabs) and secondary poly-HRP-anti-rabbit IgG (Immunologic) for 30 minutes. The slides were washed with phosphate-buffered saline, incubated with 393-diamino benzidine substrate chromogen system (Dako), and counterstained with hematoxylin (Merck).
Flow cytometry
Thymocytes and thymic lymphoma cells were stained with Thy1-PE, CD4-PacificBlue, CD8-FITC (fluorescein isothiocyanate), CD25-PerCP-Cy5.5, CD44-APC, TCRb-APC, and CD24-PE (BD Biosciences). Apoptotic thymocytes were determined using an antibody against annexinV (annexinV apoptosis kit, BD Biosciences) and propidium iodide (PI) counterstain. All experiments were performed using a multicolor CyAn flow cytometer (Beckman Coulter). Data were analyzed with FlowJo software (Treestar).
Western blot analysis
For western blot analysis, tissues and cells were lysed in radioimmunoprecipitation assay buffer (20 mM Tris, pH7.5, 150 mM sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% sodium dodecyl sulfate), protease inhibitors (Roche), phosphatase inhibitors, 5 mM trichostatin A, and 1 mM nicotinamide. We used 20 mg of total protein for western blotting and incubated it with antibodies against Hdac1 (IMG-337, Imgenex), Hdac2 (SC-7899, Santa Cruz), Hdac3 (Cell Signaling), Hdac8 (Santa Cruz), and g-tubulin (T6557, Sigma). Protein levels were quantified using IRDye 680/ 800CW secondary antibodies (Li-Cor). Nitrocellulose membranes were stained and imaged with the LI-COR Odyssey infrared imaging system. Other antibodies used are against p19
Arf (Ab80; Abcam), p53 (IMX25, Novocastra), c-Myc (N-262, Santa Cruz), green fluorescent protein (GFP) (11814460001, Roche) acetylated H3 (06599, Millipore), acetylated H4 (06866, Millipore), histone H3 (Ab1791, Abcam), histone H4, and horseradish peroxidase coupled secondary antibodies (Dako). Western blots were stained with enhanced chemiluminescence (Pierce), imaged, and quantified with ChemiDoc software (BioRad).
Southern blot analysis
Genomic DNA (10 mg) of tumor samples or primary thymocytes was digested with EcoRI overnight at 37°C. The DNA fragments were separated on a 0.8% agarose gel and transferred to a nitrocellulose membrane. The blots were hybridized with a 32 P-labeled probe harboring the Jb2 region of the TCRb locus.
HDAC activity assay
Lysates from fresh thymocytes were assayed for HDAC activity using the HDAC fluorimetric activity assay kit (Enzo life Sciences)
Comparative genomic hybridization
Genomic DNA was isolated from tumor samples using the Puregene purification kit (Qiagen). As a reference, we used genomic tail DNA from the same mouse. Tumor and tail DNA were Cy3 and Cy5 labeled using the Dual Color labeling kit (Nimblegen) according to the manufacturer's instructions. Labeled DNAs were hybridized onto mouse comparative genome hybridization (CGH) 12 3 135K whole-genome tiling arrays. The arrays were scanned on an Agilent scanner (model G2505B) at a resolution of 2 mm double pass at 100% gain of photo multiplier tubes for both channels. The data were analyzed with NimbleScan software (Nimblegen). aCGH data were deposited at the GEO database: accession number GSE43407
Chromosome spreads
Cells were incubated for 90 minutes in medium with 0.05 mg/mL colcemid (Gibco). Hereafter, the cells were washed with phosphate-buffered saline and resuspended in 75 mM potassium chloride and incubated at 37°C for 10 minutes. Subsequently the cells were fixed in methanol/acetic acid (3:1) and dropped on microscope slides. These slides were dried and cells were mounted with Vectashield/DAPI (Vector Laboratories).
Methylation genomic DNA tumors
Genomic DNA was isolated and digested with methylation-sensitive (HpaII) or -insensitive restriction enzymes (MspI) and analyzed on DNA Southern blots. As a probe for methylation analysis of minor satellites, we used pMR150. 
Tissue Microarray
A tissue microarray (TMA) was generated by collecting 3 cores of tumor or normal tissue, as determined by hematoxylin-eosin-stained paraffinembedded lymphomas as well as 3-week-old thymi. For control and orientation purposes, cores of paraffin-embedded wild-type liver were included in the TMA. Cores were embedded in a paraffin block and subsequently sectioned in 3-mm slides. Hdac1, Hdac2, and p53 staining were performed as described above. Hdac1 staining and Hdac2 staining were used to confirm the genotype of the lymphoma. Scoring for p53 staining intensity was performed by using a p53-mutant lymphoma as a positive control and wild-type thymus as a negative control. A score was assigned only when all 3 cores showed a consistent staining pattern.
p53 status assessment by sequencing, g-irradiation, and Nutlin-3 treatment
To determine p53 sequence, genomic DNA of primary thymocytes and tumor cell lines was isolated with a DNeasy Blood & Tissue kit (Qiagen). p53 exon 2-11 were PCR amplified and sequenced on a 3730 DNA analyzer (Applied Biosystems). To determine DNA damage-mediated p53 induction, thymocytes were irradiated with 6 Gy using the Gammacell 40 EXACTOR and tumor cell lines were treated with 8 mM Nutlin-3 (Cayman Chemical). Irradiated thymocytes were cultured for 16 hours and treated with Nutlin-3 for 6 hours and subsequently analyzed for p53 protein expression. For the apoptosis assay, 2 3 10 6 fresh thymocytes were irradiated with 0, 2, 4, 6, 8, and 10 Gy and cultured for 16 hours. Apoptosis was assayed by staining with annexinV and PI and performing subsequent analysis by flow cytometry (FITC-annexinV apoptosis kit, BD-Biosciences).
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed by cross-linking chromatin from 5 3 10 7 p53 2/2 T-cell lymphoma cells expressing GFP, Hdac1-GFP, or Hdac2-GFP (R.H.W and J.-H.D, unpublished results) using 1% formaldehyde for 10 minutes at room temperature. Cross-linking was stopped in 1.25 M glycine for 5 minutes on ice. Chromatin was subsequently sonicated in lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS, protease inhibitors [Roche]) using a probe sonicator (Bandelin, cycle 90%, output 8, 15 seconds on/off) and subsequently diluted in dilution buffer (10 mM Tris-HCl pH 8.0, 160 mM NaCl, 5 mM EDTA, 1% Triton X-100, protease inhibitors). Chromatin was incubated overnight with 10 mL of 10% bovine serum albumin-blocked GFP-Trap beads (ChromoTek) in dilution buffer at 4°C. Chromatin-bound beads were washed with radioimmunoprecipitation assay buffer (50 mM TrisHCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% NaDOC, 1% NP-40, protease inhibitors) and with Tris-EDTA (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).
To elute chromatin, the beads were incubated in Tris-EDTA plus 2% SDS at 65°C for 15 minutes while shaking. Cross-links were reverted by incubating chromatin at 68°C overnight with proteinase K. DNA was purified using MinElute PCR purification columns (Qiagen) and subjected to quantitative PCR using the Roche LightCycler system. Primers used for qPCR are Jdp2 59 UTR: 59-TGTGAGCTGTCACCCATCAT-39, 59-CCA CCCCAGATAGAGAAGCA-39; Jdp2 intron 1-2: 59-ATGCTATGGC TCTGCGTTCT-39, 59-TGACCCCTCAAGACAACCTC-39.
Results

Spontaneous lymphomagenesis in MxCre
1
;Hdac1 L/L and
To study HDAC function in vivo, we previously generated conditional knockout alleles for Hdac1 5 and Hdac2. 17 While interferon-inducible MxCre-recombinase-mediated deletion of Hdac1 and Hdac2 in the hematopoietic system resulted in anemia and thrombocytopenia-related death, 5 we noted that aging, uninduced, MxCre To test whether Hdac1 and Hdac2 suppress tumorigenesis in a dosagedependent manner, we generated a thymocyte-specific series of inactivated Hdac1 and Hdac2 alleles using Lck-promoter-driven Crerecombinase expression. Western blot analysis of isolated thymocytes from these mice indicated efficient deletion of Hdac1 and Hdac2 (supplemental Figure 2A,B) . Ablation of Hdac1 resulted in elevated Hdac2 protein levels, while class I Hdac3 and Hdac8 proteins levels were unaffected (supplemental Figure 2B) . While Hdac2 deficiency did not result in increased Hdac1 proteins levels, loss of 1 allele of Hdac1 in the absence of Hdac2 resulted in elevated Hdac1 protein levels. These results suggest compensatory regulation of Hdac1 and Hdac2 protein levels in thymocytes (supplemental Figure 2B) .
Deletion of combinations of Hdac1 and Hdac2 alleles resulted in differential effects on global HDAC activity, as HDAC-activity measurements in 1-week-old thymocytes revealed a progressive loss of global HDAC activity in wild-type . Figure 1D ). Tumors across genotypes were identified as thymic lymphomas, which disseminated predominantly to lung, kidney, liver, and lymph nodes (supplemental Figure 2C,D) . Mono-allelic expression of Hdac1 Figure 1E ; supplemental Figure 2E ). These findings were corroborated by the appearance of a thymic lymphoma in 1 of 10 LckCre;Hdac1 1/D ;Hdac2 1/D mice at 46
weeks that lost Hdac1 and retained Hdac2 expression ( Figure 1D and supplemental Figure 2F ). Genetic analysis of this tumor indicated loss of the wild-type Hdac1 allele and maintenance of 1 wild-type Hdac2 copy, thereby recapitulating Hdac1 D/D ;Hdac2
tumors (supplemental Figure 2G) . This result suggests that reduced Hdac1 and Hdac2 levels generate a tumor-prone condition that allows in vivo selection for Hdac1 loss of heterozygosity. In summary, we established, for the first time, a tumor suppressor function for Hdac1 and Hdac2, which act collectively in a dosage-dependent manner. Figure 2H) . In summary, although Hdac1 and Hdac2 suppress lymphomagenesis in a dosage-dependent manner, complete inactivation of Hdac1 and Hdac2 abrogates lymphomagenesis. Figure 2F ), indicating the proliferative capacity of the expanded ISP population. These data indicate a crucial role for Hdac1 and Hdac2 in the regulation of pre-T-cell development by controlling ISP thymocytes, a T-cell developmental stage that was previously implicated in lymphomagenesis. 30 The correlations between global HDAC activity, tumor latency, and tumor incidence and ISP thymocyte numbers strongly suggests that Hdac1 and Hdac2 suppress lymphomagenesis by controlling ISP thymocytes in a dosage-dependent manner. Figure 3D and supplemental Figure 3A ,B), demonstrating that complete ablation of Hdac1 and Hdac2 is not compatible with developmental progression of early thymocytes and consequently prevents tumorigenesis. Collectively, our results show that a gradual decrease in Hdac1-and Hdac2-governed HDAC-activity predisposes to tumorigenesis, whereas complete loss of Hdac1 and Hdac2 prevents oncogenic transformation. For personal use only. on July 10, 2017. by guest www.bloodjournal.org From transcriptional changes were found in Notch1 targets (data not shown, supplemental Figure 5A ). Furthermore, no amplification or overexpression of the p53 antagonists Mdm2 and Mdmx was observed in these lymphomas ( Figure 4B and supplemental Figure 5A Figure 5G ). These findings suggest that reduced Hdac1-and Hdac2-governed HDAC activity in thymocytes resulted in an impaired p53 pathway, which bypasses the requirement for p53 mutations in c-Myc-induced lymphomagenesis.
Consequently, impaired p53 function may allow clonal outgrowth of c-Myc overexpressing thymocytes but also tolerate mitotic slippage resulting in chromosome 15 trisomy.
Hdac1 and Hdac2 regulate Myc-collaborating genes
As transcriptional regulation is a prime function of Hdac1 and Hdac2, we used Hdac1 and Hdac2 transcriptomes in thymoyctes and lymphomas to obtain insight into Hdac1/2-mediated suppression of lymphomagenesis. In agreement with reduced HDAC activity Figure 6A and Figure 1D ). Since chromosome 15 trisomy and Myc overexpression was a common feature of Hdac1/2 lymphomas, we investigated whether genes deregulated in these lymphomas were enriched for genes able to collaborate with Myc in oncogenic transformation. Among the deregulated genes we identified, a significant enrichment (164 of 410 mapped transcripts; Fisher exact test, P 5 6. 13e-34 ) of CTGs previously found in insertional mutagenesis screens aimed at identifying Myc collaborating genes in lymphomagenesis 28, 29 ( Figure 6C and supplemental Table 3 ). These data indicate that Hdac1 and Hdac2, in a dosage-dependent manner, regulate the expression of genes able to synergize with c-Myc in oncogenic transformation of thymocytes. a transcript with unknown function 2010107G12RIK, and Ephrin type-B receptor 2 (Ephb2) [36] [37] [38] ( Figure 6D ). The Jdp2 gene specifically drew our interest as Jdp2 is targeted in insertional mutagenesis screens with high frequency in Myc overexpressing lymphomas. 28, 29 In addition, Jdp2 was preferentially activated by insertional mutagens in murine p53 1/2 lymphomas that retained the p53 wild-type allele and was shown to suppress p53 expression. Figure 6A and Figure 6D ,E). These data suggest that Hdac1/2 levels directly regulate Jdp2 that subsequently, in a dosage-dependent manner, represses p53. Indeed, chromatin immunoprecipitation experiments using T-cell lymphoma cell lines expressing GFP-tagged versions of Hdac1 and Hdac2 revealed a direct binding of Hdac1 and Hdac2 to a Jdp2 intron 1-2 promoter region in contrast to a more 59 UTR region of the Jdp2 locus ( Figure 6F ). Moreover, downregulation of Jdp2 using 2 independent Jdp2 shRNAs resulted in rapid cell death of Hdac1 D/D ;Hdac2 1/D lymphoma cells but did not affect the survival of a p53 2/2 lymphoma cell line ( Figure 6G and supplemental Figure 6B ), suggesting that Jdp2 is critical for the survival of lymphoma cells in a p53-dependent manner. Collectively, the data presented here demonstrate that Hdac1 and Hdac2 function in a dosage-dependent manner as a p53-dependent barrier to prevent oncogenic transformation of Myc overexpressing thymocytes through transcriptional regulation of p53 suppressors like Jdp2.
Discussion
In summary, using a unique mouse model displaying a gradient of Hdac1 and Hdac2 governed HDAC activity, we provide genetic evidence for a previously unknown dosage-dependent tumor suppressor function for Hdac1 and Hdac2. In contrast to HDAC-activity-independent chromosome 15 trisomy associated c-Myc upregulation, we observed HDAC-activity-dependent histone 3 H hyperacetylation and associated gene deregulation in preleukemic thymocytes. The significant enrichment of Myccollaborating genes (MCGs) among the deregulated genes attest to the importance of Hdac1 and Hdac2 as critical regulators of genes that determine cellular fate upon oncogenic insults such as Myc overexpression. MCGs have been shown to synergize with c-Myc in tumorigenesis by inactivating the tumor-protective p19 Arf -Mdm2-p53 pathway. 35 Figure 6E) . A rationale for the latter observation is provided by the known p53 suppressing activity of Jdp2, 37 which alleviates the need to inactivate p53 upon an oncogenic insult and may also explain why activating retroviral insertions in Jdp2 strongly accelerated Myc-driven lymphomagenesis. 28 We identified deregulated expression of other MCGs regulating p53 function next to Jdp2 Dyrk3 was shown to impair p53 activity through phosphorylation of Sirt1. 36 In addition, Lpar2 was shown to collaborate with c-Myc oncogenic transformation and allowed bypass of p53-induced senescence in the presence of wild-type p53, suggesting a role for Lpar2 in regulating the p53 fail-safe function. 38, 40 Although we cannot exclude that these Hdac1/2-regulated genes also contributed to lymphomagenesis, the fact that these MCGs do not regulate p53 transcription suggests that Jdp2 is a crucial contributor to the tumor phenotype. Together these results indicate a role for Hdac1-and Hdac2-governed HDAC activity in preventing "transcriptional instability." Gradual loss of HDAC activity will result in a gradual increas in transcriptional instability, providing the cell with a repertoire of misexpressed proteins. Upon encountering an oncogenic insult, such as c-Myc overexpression, selection from the misexpressed protein repertoire for the most advantageous combination, including proteins inactivating p53 function, will generate a volatile situation that facilitates tumorigenesis (supplemental Figure 6C) .
Previously, we showed that loss of Hdac1 and Hdac2 in mouse embryonic fibroblasts resulted in a senescence-like growth arrest independent of p16 Inka /p19
Arf and p53, suggesting that other pathways are involved in mediating the loss of Hdac1 and Hdac2. 5 Although the mechanism underlying the developmental block during T-cell differentiation in DKO mice remains elusive, it is tempting to speculate that similar pathways are activated upon loss of Hdac1 and Hdac2 in thymocytes. Identification of these pathways may also provide insights into the early thymocyte block in DKO mice.
Our findings provide a cautionary note on the use of HDACi in the clinic as these agents may enable therapy-induced tumorigenesis. Although constitutive genetic inactivation of HDACs is different from temporal, chemical inactivation of HDAC activity using HDACi, the progression of Hdac1 41 Moreover, several studies have shown that inactivation of epigenetic regulators may result in adverse effects such as tumorigenesis. Genetic inactivation of the epigenetic regulators DNA methyltransferase 1 (Dnmt1), histone deacetylase 3 (Hdac3), and Sirtuin 2 (Sirt2) resulted in tumor formation in mouse models. 31, 42, 43 Moreover, cancer genome sequencing projects have revealed recurrent mutations in methyltransferase EZH2 44 and DNA methyl transferase DNMT3A, 45 underscoring the potential adverse effects of small molecule inhibitors on these enzymes in the treatment of (cancer) patients.
Although genetic alterations affecting HDAC1 and/or HDAC2 in human T-cell acute lymphoblastic lymphomas (T-ALL) have not been identified, full genome sequencing identified mutations affecting known HDAC1 and HDAC2 interactors, such as BCL11B 46 and RUNX1. 22, 47 The identification of HDAC1-and HDAC2-negative tumor specimen in various other tumor types 48, 49 encourages the analysis of T-cell lymphomas for HDAC1 or HDAC2 expression.
Despite the concerns raised by our studies regarding HDACi treatment, they simultaneously revealed that reduced HDAC activity generates a cancer cell vulnerability. Since critical HDAC activity levels are required to sustain tumor cells, one can envision increased HDACi sensitivity of tumors displaying reduced HDAC activity. Less remaining HDAC activity needs to be inactivated to reach the HDAC-activity threshold that is critical for viability. Indeed, our data showed an increased responsiveness of tumors displaying relatively low HDAC activity toward pharmacological inhibition of HDACs. Therefore, identification of tumors with low HDAC levels, as has been observed in some tumor types, 48, 49 in contrast to high HDAC expression, may be used as a biomarker to predict HDACi responsiveness and to stratify cancer patient populations.
